The group’s principle activities include discovering and developing new medicines to stop cancer. The group’s pipeline targets include pivotal role of Bcl-2 of proteins and targeting Bcl-2, Bcl-Xl and Mcl-1 to trigger apoptosis. The group operates from United States.